Hofseth BioCare ASA

Oslo Stock Exchange HBC.OL

Hofseth BioCare ASA Price to Sales Ratio (P/S) on January 14, 2025: 3.61

Hofseth BioCare ASA Price to Sales Ratio (P/S) is 3.61 on January 14, 2025, a -26.07% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Hofseth BioCare ASA 52-week high Price to Sales Ratio (P/S) is 5.01 on January 19, 2024, which is 38.83% above the current Price to Sales Ratio (P/S).
Hofseth BioCare ASA 52-week low Price to Sales Ratio (P/S) is 2.22 on December 03, 2024, which is -38.52% below the current Price to Sales Ratio (P/S).
Hofseth BioCare ASA average Price to Sales Ratio (P/S) for the last 52 weeks is 3.71.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Oslo Stock Exchange: HBC.OL

Hofseth BioCare ASA

CEO	Mr. Jon Olav Odegard
IPO Date	Dec. 2, 2011
Location	Norway
Headquarters	Kipervikgata 13
Employees	69
Sector	Health Care
Industries Pharmaceuticals Biotechnology Cosmetics

Description

Hofseth BioCare ASA engages in providing value added biomarine ingredients for human and animal applications in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol and cardiovascular function; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; CalGo, a marine calcium powder produced to support cartilage function and joint health; CollaGo, a collagen peptide powder to enhance the beauty of hair, skin, and nails; and PetGo, a non-soluble protein. The company distributes its products through distributors, agents, and its own sales force. It has a research agreement with Stanford University School of Medicine for pre-clinical and clinical research on necrotizing enterocolitis and irritable bowel syndrome. The company was founded in 2000 and is headquartered in Ålesund, Norway.

Key trends

Past 5 years